Abby Hardy, Author at BioTuesdays

Developments

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Cerevel Therapeutics (NASDAQ:CERE) dosed the first patients in each of its three Phase 3 trials evaluating tavapadon for the treatment of Parkinson’s disease (PD). Tavapadon is an oral, once-daily partial agonist...

October 30, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx (NASDAQ:BLRX) launched a Phase 2 trial evaluating motixafortide, in combination with cemiplimab and standard-of-care chemotherapy, in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...

October 29, 2020

Developments

MediWound completes enrollment in Phase 3 pediatric burn study

MediWound (NASDAQ:MDWD) completed enrollment in a Phase 3 study evaluating NexoBrid for the treatment of burns in patients 18 years of age and younger. NexoBrid is a topically administered biological product that...

October 29, 2020

Developments

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

IntelGenx (TSXV:IGX; OTCQB:IGXT) signed a binding letter of intent (LOI) with Heritage Cannabis (CSE:CANN; OTCQX:HERTF) for the supply of CBD-containing filmstrip products for the Canadian and Australian markets. Under...

October 29, 2020

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-104 for the treatment of SURF1-associated Leigh syndrome. Leigh syndrome is a severe neurological disorder that...

October 27, 2020

Executive Moves

Fibrocor names William Fanslow as SVP drug development

William Fanslow Closely-held Fibrocor Therapeutics appointed industry veteran, William Fanslow Ph.D., as SVP of drug development. Dr. Fanslow has more than 20 years of experience in drug development, including both...

October 26, 2020

Developments

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported the agenda for its KOL virtual investor event taking place on Oct. 29 at 12:00 pm ET. Presenters include Jim Hutchens, Imagin’s...

October 26, 2020

Author - Abby Hardy

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

MediWound completes enrollment in Phase 3 pediatric burn study

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Taysha gets FDA rare pediatric and orphan drug designations for Leigh syndrome

Fibrocor names William Fanslow as SVP drug development

Imagin Medical reports agenda for KOL virtual investor event on Oct. 29

General

More